Reading UFPT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UFPT free→Reading UFPT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UFPT free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but earnings quality and management's track record are neutral. Risk is moderate, and the sector backdrop presents a headwind. Compared with sector peers, UFPT is above typical. Peer multiples imply a price about 6% below where it trades (it looks expensive on this basis); the read is fair. If UFPT cuts guidance on the next call, that could have a meaningful negative impact. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $233.66. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $234 UFPT trades at 25× p/e, in line with its 23× p/e peer median. Our $229 fair value reflects that, high confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 2% near-term growth, in line with our forecast of about 5%. This describes what's priced in, not a forecast of the move.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.18x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $2.51 → $2.56 (+1.9% / 30d). 3 raised, 1 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d. 50% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$121.
How much price usually moves either way.
On a bad day, this stock has moved -$382.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,069.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings will show if the company can keep growing. This is important during challenges.
Confirms one read:Q2 earnings report shows net income growth higher than 1.4% year-over-year.
Confirms the other:Q2 earnings report shows net income growth lower than 1.4% year-over-year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for UFPT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
by reference. Stock Unit and Performance Share Awards As previously disclosed, in connection with the appointment of Mitchell C. Rock as the Company’s Chief Executive Officer, the Compensation Committee approved Mr. Rock’s employment offer, which provided that he would be eligible to receive a one-time grant of $650,000 worth of restricted stock units, subject to a three-year vesting period to be awarded upon appointment as Chief Executive Officer. At its June 4, 2026 meeting, the Compensatio…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
UFPT UFP Technologies, Inc. | Above typical Show detailsSector percentile: 96 of 100 | full | moderate |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 92 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Increase capacity with two new facilities in La Romana and Santiago to support growth in robotic surgery and safe patient handling.
Prioritize MedTech segments like robotic surgery, patient surfaces, and interventional and surgical segments for growth.
Continue to assess acquisition opportunities to enhance customer value and expand capabilities.
Focus on increasing revenue through strategic initiatives and market expansion.
Continue to focus on maintaining strong operating income through cost management and efficiency.
Why it matters: Improving cash flow is crucial for funding growth. A rise above $10M would show progress.
Confirms:Cash flow from operations reported above $10M in Q2.
Disproves:Cash flow from operations remains below $10M in Q2.
Why it matters: Growth from these facilities is important. It helps meet demand in robotic surgery.
Confirms:Q2 revenue growth from medical sales exceeds 5.9% as new facilities ramp up.
Disproves:Q2 revenue growth from medical sales is below 5.9%. This is despite new facilities.
Why it matters: Strong growth in medical sales is key for UFP's overall revenue. A rise above 5.9% shows momentum.
Confirms:Q2 medical sales growth reported above 5.9% year over year.
Disproves:Medical sales growth reported below 5.9% year over year.
Why it matters: New acquisitions may improve UFP's market position and growth. Announcements show progress.
Confirms:Announcement of a new acquisition that fits UFP's growth strategy.
Disproves:No new acquisitions announced by the end of Q2.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of General Counsel, Secretary, and Senior Vice President of Human Resources On May 19, 2026, Christopher P. Litterio, General Counsel, Secretary, and Senior Vice President of Human Resources, informed UFP Technologies, Inc., a Delaware corporation (the “ Company ”), that he plans to retire from the Company after a period of transition . S…
Results of Operations and Financial Condition. On May 4, 2026, UFP Technologies, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1. Limitation on Incorporation by Reference. The information furnished in this Item 2.02, including the press release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…
Results of Operations and Financial Condition. On February 24, 2026, UFP Technologies, Inc. issued a press release announcing its fourth quarter and year-end financial results for the year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. Limitation on Incorporation by Reference. The information furnished in this Item 2.02, including the press release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securi…
Entry into a Material Definitive Agreement. On February 19, 2026, through a wholly-owned subsidiary, UFP Technologies, Inc. (“UFP” or the “Company”) and Intuitive Surgical SARL, one of the Company’s strategic medical customers (the “Customer”), entered into Amendment No. 27 (the “Amendment”) to the Manufacturing Supply Agreement, dated April 25, 2014 (the “Supply Agreement”, as amended, the “Amended Supply Agreement”). Effective January 1, 2026, the Amendment: 1. Extends the term of the Suppl…